Vaccines Enter the New Age of Adjuvants
This article was originally published in RPM Report
The US vaccine industry is a year away from a wave of new, more effective and longer-lasting adjuvant-enhanced products. The technology promises added protection to patients-and extra proprietary rights to product marketers.
You may also be interested in...
Pfizer’s $3.3 billion acquisition of King eliminates the primary opportunity for investors to play in the abuse-resistant formulation space and renewed questions about the logic of perpetual expansion atop Big Pharma. But the realities of the abuse resistant marketplace suggest it makes a good case for scale and diversity. Is this a sign of things to come in other drug classes?
Former MedImmune CEO David Mott discusses the key regulatory and reimbursement risks in drug development. While he sees plenty of venture capitalist money for truly innovative products, there are several areas he tends to avoid at all costs: vaccines, antibiotics, diabetes and-over the longer term-oncology drug development.
The positive view of vaccines has eroded over time from miracle of medicine to another highpriced Big Pharma product. With renewed commercial success, vaccines are being greeted with skepticism by several segments of the population including some of the public health establishment that was a pillar to vaccines during the lean years for the industry. It’s time to bridge the vaccines trust gap and here’s how.